Skip to main content

TNF inhibitor

RheumNow Podcast – Falling or Falling in Love?

May 06, 2021

Dr. Jack Cush reviews the best journal articles from the past week on RheumNow.com.

Read Article

ARTIC REWIND - Don't Half DMARD Therapy

May 06, 2021

The ARTIC-REWIND study examined rheumatoid arthritis (RA) patients in remission on conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) to see if they could "step-down" their csDMARDs theray; but  the study showed that 25% those who went on half-dose experienced disease

Read Article

Drug Monitoring Ineffective with Infliximab Treatment

May 05, 2021

The predictive value of therapeutic drug monitoring (TDM) while on biologics is debateable; gastroenterology routinely relies on TDM, while rheumatologists do not. A randomized trial compared TDM to no TDM in patients receiving infliximab for chronic immune-mediated inflammatory diseases (

Read Article

ACR Updates COVID-19 Vaccine Guidance- April 2021

ACR COVID-19 Vaccine Clinical Guidance Task Force
Apr 30, 2021

The ACR COVID-19 Vaccine Clinical Guidance was originally published on February 8, 2021 and updated on March 4, 2021. On April 28, 2021, new recommendations were added regarding mycophenolate, methotrexate, acetaminophen, and NSAID timing considerations,  

Read Article

Dual IL-17 Targeting is Effective but has More Candidiasis

Apr 27, 2021

Bimekizumab (BIM) is a monoclonal antibody that targets both interleukin-17A and interleukin-17F, which as a biologic target has worked well in the management of psoriatic disease. The current issue of the NEJM has two reports wherein BIM was shown to be more effective than secukinumab and

Read Article

Golimumab Effective in non-radiographic Axial Spondyloarthritis

Apr 26, 2021

The GO-AHEAD study was designed to assess the long-term efficacy and safety of golimumab (GLM) in non-radiographic axial spondyloarthritis (nr-axSpA).  After the 16-week, placebo [PBO]-controlled double-blind phase, 189/198 (95.5%) entered the long-term extension (OLE) for 36 weeks wherein

Read Article

BSRBR: Demyelinating Disease Following Anti-TNFα Therapy

Apr 21, 2021

Analysis of patients receiving anti–tumor necrosis factor α (TNFi) therapy in the British Society for Rheumatology Biologics Register (BSRBR) shows that the risk of demyelination is rare but is marginally incrased by taking TNFi therapy. 



From their large registry (n=13,489) they

Read Article

DMARD Dropouts During COVID-19

Apr 12, 2021

A full year from the onset of the SARS-COV-2 pandemic, rheumatologists are still seeing the consequences of COVID, with many patients avoiding usual care, follow-up visits, routine lab testing and with many self-stopping their antirheumatic meds, because it seemed like the right thing to do

Read Article

Rheumatology Care Derailed by COVID-19

Apr 06, 2021

A survey study from the  ArthritisPower PPRN or CreakyJoints database shows that during the COVID-19 pandemic patient care was substantially affected in unforeseen ways.



Data from the ArthritisPower Patient-Powered Research Network and CreakyJoints patient community were gathered by

Read Article

Psoriatic Disease Management - RNL 2021 Highlights

Mar 29, 2021

This year’s coverage of psoriatic arthritis was once again, both exciting and informative. Topics included an overview of the latest therapeutic options, an excellent discussion on psoriasis specifically, and the epidemiology of psoriatic arthritis. 

Read Article

Safety of Paternal DMARD or Biologic Use

Mar 22, 2021

A large cohort study of expectant fathers treated for immune-mediated inflammatory diseases (IMIDs) failed to show any detrimental effect from paternal exposure to immunosuppressive or biologic agents on offspring outcomes.

Read Article

Apremilast Equals MTX in Palmoplantar Psoriasis

Mar 18, 2021

Palmoplantar psoriasis (PPP) is a therapeutically challenging variant of psoriasis; nonetheless, a prospective, randomized, active-controlled trial from India suggests that apremilast is effective and safe in patients with PPP.

Read Article

RheumNow Podcast – Pounds of Prevention (3.5.2021)

Mar 04, 2021

Dr. Jack Cush reviews and discusses nearly a dozen news reports and journal articles from the past week on RheumNow.com.

Read Article
We are three weeks out from RheumNow Live. Are you planning on attending? https://t.co/vJlU0Z3Q3x

Dr. John Cush @RheumNow( View Tweet )

Feb 26, 2021

Measureable Benefits to Treat-to-Target Management in RA

Feb 24, 2021

Desai and colleagues have published that when a learning collaborative group focused on a treat‐to‐target approach was compared to usual care, a modest but significant impact on implementation, treatment changes and patient outcomes in RA patients managed with a treat‐to‐target approach was seen

Read Article
Download Available--TNF Inhibitor -Cycle TNFi or Switch MOA? https://t.co/PgmTDYltpX

Dr. John Cush @RheumNow( View Tweet )

Feb 16, 2021
No increased risk of cancer with TNFi use in PsA patients @RWCSmtg @JointMD https://t.co/7VSI1Fd1hw
Dr. John Cush @RheumNow( View Tweet )
Feb 12, 2021

Weekly Semaglutide for Weight Loss in Adults

Feb 11, 2021

NEJM has reported the results of a trial showing semaglutide once weekly plus lifestyle intervention was associated with sustained, weight loss in overweight or obese adults; such that nearly one-third lost over 20% of their body weight.



Semaglutide, a once weekly glucagon-like

Read Article

ACR Promotes New COVID-19 Vaccine Clinical Guidance for Rheumatic Patients

Feb 10, 2021

The American College of Rheumatology has published a draft guidance on the use of COVID-19 vaccination in rheumatic disease and musculoskeletal disease patients, based on the efforts of the North American Task force. The document provides guidance to rheumatology providers on the use of the

Read Article

Synovial Tissue Signature Guiding Targeted IL-6 Therapy in RA

Feb 09, 2021

RNA sequencing and classification of RA subsets has proven useful. RNA sequencing-based stratification of RA synovial tissue showed stronger associations with clinical responses compared with histopathological classification. Additionally, for patients with low or absent B-cell lineage

Read Article

Comorbidity and Drugs Drive COVID-19 Severity and Survival in Rheumatic Disease

Feb 09, 2021

While comorbidities are associated with severe COVID-19 infection, it appears they also influence severity and survival in rheumatic disease (RMD), according to a a French cohort study,



Analysis of a French RMD cohort with SARS-CoV-2 infection analyzed the effect of inflammatory

Read Article
QD Clinic Podcast from Last week. iTunes https://t.co/FHJv01AAbC or SoundCloud https://t.co/dfSTkSbY2d QD Clinics (123-127; Feb 5) QD127 - Chronic Monarthritis QD126 - Fever by the Numbers QD125 - "What Were You Thinking" QD124 - No Win Consults QD123 - When RA Meets UC https://t.co/ReOFOVooje
Dr. John Cush @RheumNow( View Tweet )
Feb 08, 2021

RheumNow Podcast – Tofacitinib Safety Concerns (2.5.2021)

Feb 05, 2021

Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.

Read Article

Cardiac and Cancer Signals Tofacitinib Safety Alert from FDA

Feb 04, 2021

The FDA has notified healthcare professionals of a safety alert concerning tofacitinib (Xeljanz), noting that preliminary results from a long-term safety clinical trial show an increased risk of serious heart-related problems and cancer with tofacitinib (compared to adalimumab) when given to

Read Article
Download available--13 New Agents in Rheumatoid Arthritis https://t.co/s2U8qm1lLs

Dr. John Cush @RheumNow( View Tweet )

Feb 04, 2021
×